drugset / Trial / NCT00389402
BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes
Phase 4
Completed
120 enrolled
International Antiviral Therapy Evaluation Center
Gilead Sciences · collabHoffmann-La Roche · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to assess differences in changes in plasma lipids between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine as a first-line regimen in patients previously naive for antiretroviral therapy. This study is an extension from the SSAR 2004/0002 which randomised patients over the same treatment arms.
Timeline
- Start
- 2006-07
- Primary completion
- —
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | — | — |
| Subject | Saquinavir | Small molecule | — | — |
| Background | Ritonavir | Other / unclassified | — | — |